Hematology First Half Recap: 2025

Although hematology has experienced a relatively slow year compared to other specialties, it has not been without advancements of its own. The approval of fitusiran and the Orphan Drug designations distributed by the US Food and Drug Administration (FDA) have been groundbreaking, and drugs still in the pipeline like iptacopan and ruxoprubart are moving towards regulatory decision quickly.